Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca
SOKA, Japan–(BUSINESS WIRE)–Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan� (“i2.JP”; Website: https://www.i2jp.net/en/index.html), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii).
i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal is to contribute to next-generation healthcare through partnerships with companies, academia, and government.
Lightnix seeks to create innovations in healthcare through the development of intradermal vaccine injection devices and other new drug delivery methods.
By leveraging its strengths in this field, the company aims to resolve healthcare issues related to vaccine and drug delivery in partnership with both the public and private sectors, including the healthcare sector and industries worldwide participating in i2.JP.
Contacts
Lightnix Inc.
Akihiro ISUMI, General Manager
+81-48-951-3637
info@lightnix.jp
https://www.lightnix.jp/en/
Recent Posts
“One Earth Summit” 2025 Held Successfully Hong Kong Fully Leverages Its Role as an International Financial Center and Leader in Green Finance
Laying a Solid Foundation for the Development of ESG Investment and Green Innovation Calling for…
The Campaign “It’s Time for EU Beef” is coming to Cebu and Manila in April
The Philippine meat industry will be shown the quality and guarantees of European beef MANILA,…
European beef will continue to play aleading role in Singapore in the coming months of 2025
"It’s Time for European Beef" is a campaign led by Provacuno and co-funded by the…
Make Waves at Galaxy Macau: Dive into a Luxurious One-Stop Ultimate Holiday Escape with the Reopening of the Grand Resort Deck
MACAU SAR - Media OutReach Newswire - 27 March 2025 - The world-class luxurious Galaxy…
Diabetes Association Unveils T-CaReMe Taipei Declaration at the Asia Diabetes International Conference
In an effort to achieve a target of 80% of patients controlling the three highs…
Li Ning Company Limited Announces 2024 Annual Results
Strengthen the “Single Brand, Multi-Categories, Diversified Channels” Strategy | Solidify Brand and Product Competitiveness, Ensure…